Liver Cancer News and Research

RSS
Liver cancer is more common in older people. Over half of people newly diagnosed with liver cancer are age 65 and over. Liver cancer is more common in men than in women. Liver cancer rates are highest among Asians and Pacific Islanders, most likely because of higher prevalence of viral Hepatitis infection. Liver cancer rates are lower among whites than Blacks or Asians and Pacific Islanders. At this time, we do not know exactly what causes cancer of the liver. There are several different types of liver cancer. The most common type is associated with long-term excessive alcoholic beverage use, scarring of the liver (cirrhosis), and Hepatitis B virus or Hepatitis C virus infection. Long-term use of anabolic steroids can also increase the risk of getting liver cancer. Smoking is also believed to increase the risk of getting liver cancer.
Mainz gastroenterologist awarded ERC Advanced Grant

Mainz gastroenterologist awarded ERC Advanced Grant

Baby boomers more likely to develop HCV

Baby boomers more likely to develop HCV

Two studies uncover limitations in screening for hepatocellular carcinoma

Two studies uncover limitations in screening for hepatocellular carcinoma

EGCG may prevent HCV reinfection after liver transplantation

EGCG may prevent HCV reinfection after liver transplantation

New 'triggered imaging' enables physicians to better target tumors during radiosurgery

New 'triggered imaging' enables physicians to better target tumors during radiosurgery

Mirna reports new preclinical data of miRNA-based therapeutic candidate for hepatocellular carcinoma

Mirna reports new preclinical data of miRNA-based therapeutic candidate for hepatocellular carcinoma

Molecular level insights into connection between cancer and diabetes

Molecular level insights into connection between cancer and diabetes

Conference highlights advances in evidence-based integrative therapies for cancer

Conference highlights advances in evidence-based integrative therapies for cancer

New studies could fundamentally change medical treatment of liver cancer

New studies could fundamentally change medical treatment of liver cancer

Encouraging interim results from daclatasvir Phase IIb study in genotype 1 and 4 HCV patients

Encouraging interim results from daclatasvir Phase IIb study in genotype 1 and 4 HCV patients

States trying to wrangle Medicaid costs; rural hospitals struggling; health hiring steady

States trying to wrangle Medicaid costs; rural hospitals struggling; health hiring steady

Economic burden of chronic hepatitis C-related liver disease

Economic burden of chronic hepatitis C-related liver disease

Tibotec to present results of TMC435 phase 2b study on HCV at AASLD 2011

Tibotec to present results of TMC435 phase 2b study on HCV at AASLD 2011

Vertex announces positive interim data from INCIVEK Phase 2 combination trial on HIV, HCV

Vertex announces positive interim data from INCIVEK Phase 2 combination trial on HIV, HCV

New data from Santaris Pharma miravirsen Phase 2a trial on HCV

New data from Santaris Pharma miravirsen Phase 2a trial on HCV

More than 36,000 people join Cancer Research UK's Voice for Radiotherapy campaign

More than 36,000 people join Cancer Research UK's Voice for Radiotherapy campaign

Vertex announces 16 grant recipients of Hep-C Circle of Care program

Vertex announces 16 grant recipients of Hep-C Circle of Care program

Jennerex commences enrollment in JX-594 Phase 2b trial for HCC

Jennerex commences enrollment in JX-594 Phase 2b trial for HCC

Galectin Therapeutics forms Liver Fibrosis Clinical Trials Advisory Board

Galectin Therapeutics forms Liver Fibrosis Clinical Trials Advisory Board

Solid organ transplant may increase risk of cancer

Solid organ transplant may increase risk of cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.